Get the Stockscreener App
5.70
5.17%
0.28
After Hours:
5.77
0.07
+1.23%
Nuvation Bio Inc stock is traded at $5.70, with a volume of 6.33M.
It is up +5.17% in the last 24 hours and up +16.33% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$5.42
Open:
$5.42
24h Volume:
6.33M
Relative Volume:
1.19
Market Cap:
$1.98B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-13.31
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
-1.89%
1M Performance:
+16.33%
6M Performance:
-33.57%
1Y Performance:
+178.05%
1-Day Range:
$5.39
$5.72
1-Week Range:
$5.33
$6.075
52-Week Range:
$2.01
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.70 | 1.98B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative? - Yahoo Finance
Is Nuvation Bio (NYSE:NUVB) Building A Global Cancer Franchise? - Kalkine Media
Doctor-turned-dealmaker reveals his M&A playbook - Pharma Voice
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Nuvation Bio Announces $200 Million Convertible Senior Notes Offering to Repay Debt and Fund Growth Initiatives - Minichart
Nuvation Bio Prices $250 Million 0.75% Convertible Notes Due 2032, Repays $58.5 Million Loan - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? - The Motley Fool
MHRA validates Nuvation Bio’s taletrectinib application in UK - Investing.com UK
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell 2000 Value Benchmark - marketscreener.com
Nuvation Bio's Taletrectinib Enters UK Regulatory Review - Moomoo
Nuvation Bio Inc.(NYSE: NUVB) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
MHRA validates Nuvation Bio’s taletrectinib application in UK By Investing.com - Investing.com South Africa
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - PR Newswire
Nuvation Bio prices $250M convertible notes offering - MSN
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes - Rockdale Citizen
Nuvation Bio to offer $200M convertible senior notes - MSN
Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB) - TradingView
Nuvation Bio prices $250M convertible notes offering By Investing.com - Investing.com Canada
Nuvation Bio Announces Proposed Convertible Senior Notes Offering - Investing News Network
NUVB Stock Builds Momentum As Charts And Cash Position Strengthen - StocksToTrade
Why is Nuvation Bio stock sliding today? - Investing.com
Nuvation Bio (NUVB) Sees Significant Decline of 10.1% - GuruFocus
Why Is NUVB Stock Falling Today? - Yahoo Finance
Nuvation Bio stock tumbles on $200M convertible notes offering By Investing.com - Investing.com Nigeria
Nuvation Bio stock tumbles on $200M convertible notes offering - Investing.com
Nuvation Bio Shares Sink Premarket With Plans for Convertible Notes Offering - marketscreener.com
Nuvation Bio plans $200 million convertible notes offering - Investing.com
Nuvation Bio plans $200 million convertible notes offering By Investing.com - Investing.com Canada
Nuvation Bio | 424B5: Prospectus - Moomoo
Nuvation Bio seeks $200M to repay debt and fund operations - Stock Titan
Nuvation Bio (NUVB) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Nuvation Bio CFO Sauvage sells $286k in stock By Investing.com - Investing.com India
Nuvation Bio chief regulatory officer sells $379k in stock - Investing.com UK
Nuvation Bio CFO Sauvage sells $286k in stock - Investing.com UK
Nuvation Bio’s chief people officer sells $753k in stock By Investing.com - Investing.com Nigeria
Nuvation Bio’s chief people officer sells $753k in stock - Investing.com
Nuvation Bio chief regulatory officer sells $379k in stock By Investing.com - Investing.com Australia
Form 4 Nuvation Bio Inc For: 24 June By Investing.com - Investing.com Nigeria
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvation Bio Inc Stock (NUVB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Markel Stacy | CHIEF PEOPLE OFFICER |
Jun 23 '26 |
Sale |
6.03 |
125,000 |
753,188 |
32,591 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Option Exercise |
2.93 |
63,000 |
184,590 |
116,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Sale |
6.02 |
63,000 |
379,191 |
53,000 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Option Exercise |
2.17 |
47,668 |
103,440 |
60,341 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Sale |
6.01 |
47,668 |
286,370 |
12,673 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):